157 results about "K pneumoniae" patented technology

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention relates to the technical field of molecular biology and pathogenic microorganism detection, and discloses a Klebsiella pneumoniae and Escherichia coli synchronous detection method based on RPA-CRISPR / Cas12a and application, and the method comprises the following steps: extracting DNA from a sample, carrying out isothermal amplification by adopting an RPA primer designed aiming at a Klebsiella pneumoniae rcsA gene and an Escherichia coli uriA gene, and carrying out amplification by adopting an RPA primer designed aiming at a Klebsiella pneumoniae RcsA gene and an Escherichia coli uriA gene; a detection system containing Cas12a enzyme, crRNA and a fluorescence report substrate is constructed, and a result is interpreted through a fluorescence or lateral flow chromatography test strip. Detection can be completed within 70 minutes at the constant temperature of 37 DEG C, the sensitivity reaches 5 * 10 copies / mu L, the specificity is high, no cross reaction exists, the kit is suitable for clinical early screening, hospital infection monitoring and on-site POCT application, and an efficient and reliable new tool is provided for pathogen diagnosis.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

This invention discloses nucleic acid aptamers that specifically bind to the OmpK36 protein and their applications. Through analysis and screening, aptamers APT-1 and APT-2 that specifically bind to the OmpK36 protein were obtained. Nucleic acid aptamer APT-1 can specifically bind to outer membrane polypeptides, while nucleic acid aptamer APT-2 can specifically bind to polypeptides specific to Klebsiella pneumoniae. Both can bind to the OmpK36 protein to form a complex structure, which can be used for the specific detection of Klebsiella pneumoniae, providing convenience for clinical detection, diagnosis and treatment, and exclusion detection of specific pathogens in SPF animals.

The invention relates to a binding protein B capable of binding with klebsiella pneumoniae and application of the binding protein B, and belongs to the technical field of molecular biology and protein engineering. The binding protein B provided by the invention can be specifically bound with an extramembrane part of a specific protein P24017. OMPAKLEPN of klebsiella pneumoniae, and experiments such as bimolecular fluorescence complementation and flow cytometry prove that the binding protein B has good recognition and stable binding capacity on the klebsiella pneumoniae, can be used for identifying and screening the klebsiella pneumoniae, and has good application prospects. And a key tool is provided for targeted drug development aiming at the bacterium.

The present invention relates to novel oligosaccharide-carrier protein conjugates of formula (I) and their use as pharmaceuticals, particularly as vaccines. The present invention also relates to related aspects, including oligosaccharide intermediates of formulas (II) and (III) and methods for preparing such conjugates. Furthermore, the present invention relates to pharmaceutical compositions comprising the oligosaccharide-carrier protein conjugates and to the use of oligosaccharide-carrier protein conjugates of formula (IV) in biological assays. [Formula 1] JPEG2025536393000131.jpg85168

The application discloses application of T1FR protein in inhibition of Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae, and relates to the field of biotechnology. T1fr The biological factor T1FR protein encoded by the gene can inhibit Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae adhesion factors, and can effectively reduce the use of antibiotics and relieve the drug resistance of Klebsiella pneumoniae and Salmonella by inhibiting pathogenic bacteria adsorption and colonization in human and animal tissues, thereby providing a theoretical basis and an important reference scheme for controlling bacterial infection and biofilm formation.

The invention discloses application of lactobacillus plantarum LP-Y01 and a fungicide thereof in preparation of a medicine for preventing and / or treating carbapenem-resistant drug-resistant bacterium infection. The invention verifies that the lactobacillus plantarum can generate a direct inhibition effect on carbapenem-resistant klebsiella pneumonia in vitro and has certain effective activity on colonization of the carbapenem-resistant klebsiella pneumonia in vivo through flora regulation and control. Probiotic pretreatment shows remarkable clinical potential by regulating and controlling a flora structure, provides a precise strategy for prevention and control of drug-resistant bacteria, and has a relatively good application prospect.

The present invention provides a Klebsiella pneumonia KPC-Pal recombinant protein, which is composed of a KPC peptide segment extracted from the Klebsiella pneumonia KPC-2 protein and a Pal peptide segment extracted from the Klebsiella pneumonia Pal protein connected by a polypeptide linker, wherein the amino acid sequence of the Klebsiella pneumonia KPC-2 protein is SEQ ID NO: 3, and the amino acid sequence of the Klebsiella pneumonia Pal protein is SEQ ID NO: 4. The present invention also provides its expression vector and recombinant engineered bacteria, as well as its application in the preparation of a preparation for diagnosing, preventing or treating Klebsiella pneumonia infection. The Klebsiella pneumonia KPC-Pal recombinant protein provided by the present invention can effectively stimulate the body to cause a protective immune response, thereby resisting the lethal infection of Klebsiella pneumonia.

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.

The application belongs to the technical field of medicine and pharmacy, and particularly relates to application of vanillin in preparation of a Klebsiella pneumoniae capsule inhibitor. The application relates to application of vanillin in preparation of an inhibitor for inhibiting formation, adhesion or function of a Klebsiella pneumoniae capsule, and related antibacterial or anti-infection products, wherein the vanillin reduces pathogenicity of Klebsiella pneumoniae by inhibiting capsule synthesis. It is disclosed that the vanillin can effectively inhibit formation of a Klebsiella pneumoniae capsule and reduce viscosity of bacteria, and can effectively treat mice infected with Klebsiella pneumoniae.

The invention relates to a primer and probe combination for simultaneously detecting urinary tract klebsiella pneumoniae, escherichia coli and drug-resistant genes through nested PCR (Polymerase Chain Reaction) and a kit of the primer and probe combination, which are characterized in that a phoE target gene is selected for primer and probe design to ensure that cross amplification of related bacteria is not caused, so that the detection specificity requirement of actual klebsiella pneumoniae is met; the Klebsiella pneumoniae and the escherichia coli can be identified at the same time, the source of the drug-resistant gene KPC can be judged, and the method is very important for clinical precise diagnosis and treatment.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The invention belongs to the technical field of microbiological detection, and particularly relates to a Klebsiella pneumoniae MLST typing primer group and method based on a hospital localized microbiological mNGS platform. The primer group comprises primer pairs for amplifying an rpoB gene, an infB gene, a pgi gene, a phoE gene, a gapA gene, an mdh gene and a tonB gene, and corresponding nucleotide sequences are as shown in SEQ ID NO: 1-14. According to the technical characteristics of short sequencing read length (50 bp) and single-ended sequencing of a next-generation sequencing platform in a hospital, the primer group for Klebsiella pneumoniae MLST housekeeping gene amplification is redesigned, and amplicons are adaptive to the sequencing working principle of the existing next-generation sequencing platform in the hospital by optimizing the length and position of the amplicons. By utilizing the primer group, the kit or the method, the genetic relationship between hospital infection pathogenic bacteria can be quickly and accurately judged (within 24 hours), the timeliness and scientificity of infection prevention and control are remarkably improved, and the primer group, the kit or the method have a wide clinical application prospect.

FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex

The application belongs to the technical field of non-antibiotic compounds as bacteriostatic agents, and discloses an application of a known non-antibiotic compound, cladrabine, in inhibiting the growth of multi-drug resistant Klebsiella pneumoniae. The application finds that cladrabine can inhibit the growth of multi-drug resistant Klebsiella pneumoniae, and the minimum bacteriostatic concentration reaches 64 mg / L. Further exploration of the bacteriostatic mechanism finds that after exposure to cladrabine, the permeability of the bacterial cell membrane is enhanced, and the macromolecular substances (nucleic acids and proteins) in the cell are excreted, causing the integrity of the bacterial cell membrane to be destroyed, and further causing the death of Klebsiella pneumoniae. The application proposes that cladrabine can destroy the cell membrane of bacteria, change the permeability of the cell membrane, has a good inhibitory effect on multi-drug resistant Klebsiella pneumoniae, and can be further applied to the preparation of related drugs.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof having potent antibacterial activity against klebsiella pneumoniae, in particular against multi-drug resistant klebsiella pneumoniae strains. The invention also relates to application of the monoclonal antibody or the antigen binding fragment thereof in treatment, prevention and diagnosis of Klebsiella pneumoniae infection, especially Klebsiella pneumoniae related diseases.

The invention relates to the technical field of bacterial detection, in particular to a primer composition for simultaneously detecting pathogenic bacteria genes and drug-resistant genes, a detection method and a detection device. The core of the invention lies in synchronous detection of two main bacteria causing sepsis, namely burkholderia pseudomallei and klebsiella pneumoniae, and key drug-resistant genes by using a loop-mediated isothermal amplification (LAMP) technology. Specifically, the primer composition comprises nucleotide sequences as shown in SEQ ID No.1-17, and can be used for detecting a burkholderia pseudomallei recA pathogenic gene, a kfB pathogenic gene of klebsiella pneumoniae, a quinolone antibiotic drug-resistant gene qnrA and a carbapenem antibiotic drug-resistant gene OXA-48 in a targeted manner. The primer composition disclosed by the invention can be used for simultaneously detecting various pathogenic bacteria genes and drug-resistant genes causing sepsis, the detection process is convenient, rapid and accurate, the detection result can be obtained within 40 minutes, and the detection effect is better.

The present application relates to a kind of binding protein B combined with klebsiella pneumoniae and its application, belong to molecular biology and protein engineering technical field.The binding protein B provided by the present application can specifically bind the membrane outer part of the unique protein P24017 of klebsiella pneumoniae OMPA_KLEPN, and its good recognition and stable binding capacity for klebsiella pneumoniae are verified by double-molecule fluorescence complementation, flow cytometry and other experiments, can be used for the identification and screening of klebsiella pneumoniae, provides key tool for the targeted drug development for the bacteria.

The invention provides a preparation method and application of alpinia oxyphylla leaf essential oil, and relates to the field of natural plant extracts. The alpinia oxyphylla leaf essential oil is applied to preparation of a bacteriostatic agent for inhibiting bacteria or / and fungi, and the bacteria comprise one or more of klebsiella pneumoniae, salmonella enterobacter and shigella flexneri. The fungi comprise one or more of candida tropicalis and malassezia furfur; the preparation method of the alpinia oxyphylla leaf essential oil comprises the following steps that alpinia oxyphylla leaves are taken, dried and smashed, the smashed alpinia oxyphylla leaves are placed in water to be soaked, the material-liquid mass ratio is 1: (15-17), and the soaking time is 0.8-1.2 h; after soaking, distillation is carried out, the distillation time is 4.5-5.5 h, and the distillation temperature is 170-200 DEG C; and after distillation is finished, collecting upper oily liquid to obtain the alpinia oxyphylla leaf essential oil. The prepared alpinia oxyphylla leaf essential oil has broad-spectrum antibacterial and bactericidal effects, and the antibacterial and bactericidal effects are good.

This application applies to the field of genetic engineering technology and provides an mlaC knockout mutant strain, its construction method, and application. The mlaC knockout mutant strain is obtained by knocking out the mlaC gene in highly virulent Klebsiella pneumoniae (hvKP). The examples of this application innovatively discovered that hvKP lacking the mlaC gene exhibited reduced lung growth and lung damage in mice, as well as reduced mortality in mice, indicating that the MlaC protein is a key pathogenic factor in hvKP. Furthermore, secretory protein profiling and Western blot results showed that the MlaC protein can be secreted extracellularly and is present in all Klebsiella pneumoniae (KP) strains. Its sequence is conserved, making it a potential new vaccine target for KP. This application broadens research on the pathogenic mechanism of KP and provides a theoretical basis for its prevention and treatment.

The application belongs to the field of genetic engineering and medical engineering, and discloses virK Application of gene in regulation of Klebsiella pneumoniae virulence. The application finds that the expression level of the gene is significantly increased in polymyxin-resistant mutant strains through transcriptome analysis, virK Further research shows that the expression of the gene is regulated by the PhoP / PhoQ two-component regulatory system. The application constructs virK Gene deletion mutant strains and complementary strains, and compares the virulence difference of the strains in an animal infection model, finds that virK The virulence of the deletion strain is significantly reduced, and the complementary strain can restore the virulence phenotype, indicating that virK The gene plays an important role in the regulation of Klebsiella pneumoniae virulence. The application first finds that PhoP can regulate virK Gene expression, and affects the virulence phenotype of Klebsiella pneumoniae through the regulation pathway, thereby revealing a new virulence regulation mechanism, and providing a theoretical basis for subsequent targeted intervention.

The application discloses a method for identifying Klebsiella pneumoniae gene circadian rhythm expression by using a bioluminescence reporting system. The application constructs a recombinant bioluminescence Klebsiella pneumoniae driven by a metabolic gene malate:quinone oxidoreductase mqo promoter (Pmqo), and directly observes the change rule of bacterial gene expression under entrainment and free-running conditions of temperature cycle by monitoring the luminescence characteristics. The luxCDABE gene operon comprises genes for coding luciferase and substrate synthesis enzyme, wherein luxA and luxB code for heterodimer luciferase, luxC, luxD and luxE synthesize aldehyde as a substrate for the luciferase luminescence reaction. The luciferase catalyzes the oxidation of aldehyde to generate visible blue-green light with a wavelength of 450-490 nm. The Lux bioluminescence reporting system has the advantages of not needing to add an exogenous substrate and not affecting the normal physiological functions of the host, and can be applied to the identification of Klebsiella pneumoniae gene circadian rhythm expression.

The embodiment of the application relates to a primer group, application and detection method of a fluorescent quantitative PCR for identifying high-toxicity Klebsiella pneumoniae, wherein the primer group comprises a primer pair of one or more of SEQ ID NO: 1 to SEQ ID NO: 26, and the primer group can improve the identification accuracy of the high-toxicity Klebsiella pneumoniae.

This application provides a method for generating emergency treatment recommendations based on Klebsiella pneumoniae classification prediction, including: acquiring Klebsiella pneumoniae case data for a set time period; identifying homologous Klebsiella pneumoniae case data based on mass spectrometry data in the Klebsiella pneumoniae case data, and integrating the homologous Klebsiella pneumoniae case data to obtain Klebsiella pneumoniae case data groups; determining the feature vector of each Klebsiella pneumoniae case data based on the Klebsiella pneumoniae case data group; inputting the feature vector of each Klebsiella pneumoniae case data into a Klebsiella pneumoniae classification model to determine the classification corresponding to each Klebsiella pneumoniae case data; and generating emergency treatment recommendations based on the classification corresponding to each Klebsiella pneumoniae case data. This solution can provide emergency recommendations during the transition period, so as to promptly attract the attention of medical staff and take appropriate measures.

The invention is applicable to the technical field of bioengineering, and provides a streptococcus suis bacteriophage antibacterial protein Lys8387 as well as a preparation method and application thereof, and the amino acid sequence of the streptococcus suis bacteriophage antibacterial protein Lys8387 is shown as SEQ ID NO.2. A novel bacteriophage antibacterial protein capable of playing splitting and depolymerizing double activities on streptococcus suis is constructed through a genetic engineering technology, and the lyase is novel in sequence, shows strong bactericidal activity on multi-drug-resistant streptococcus suis, can be independently used or compounded with other substances for use, or can be prepared into an enzyme preparation, and can be used for preparing an antibacterial agent for multiple drug-resistant streptococcus suis. The compound not only has bactericidal activity on streptococcus suis, but also has a degradation effect on capsular polysaccharide of streptococcus suis, K2 type klebsiella pneumoniae and the like, and a thought is provided for preparing a medicine for preventing and treating diseases caused by infection of microorganisms such as streptococcus suis and the like.

The invention relates to a Klebsiella pneumoniae bacteriophage vBKpnSYPH3 carrying a KPC-2 type enzyme mutant and application thereof, and belongs to the technical field of microorganisms, the bacteriophage is preserved in the China Center for Type Culture Collection on May 28, 2025, the preservation number is CCTCC No.20251208, and the preservation number is CCTCC No.20251208. The Klebsiella pneumoniae bacteriophage vBKpnSYPH3 can be used for preparing the Klebsiella pneumoniae bacteriophage vBKpnSYPH3. The bacteriophage can effectively split strains which are evolved from original strains of blaKPC-2 genes and carry mutant genes such as blaKPC-33 and the like, the bacteriophage has unique sensitivity to specific mutants of KPC enzyme, and a brand-new tool and thought are provided for solving treatment blind areas generated in the drug-resistant evolution process of bacteria.